Clinical Inquiry: what are the benefits and risks of inhaled corticosteroids for COPD?
作者信息
Hamilton Tanya, Miller John B, Vincent E Chris, St Anna Leilani
机构信息
Montana Family Medicine Residency--Riverstone Health, Billings, MT, USA.
出版信息
J Fam Pract. 2014 May;63(5):276-8.
PMID:24795909
Abstract
摘要
相似文献
1
Clinical Inquiry: what are the benefits and risks of inhaled corticosteroids for COPD?
J Fam Pract. 2014 May;63(5):276-8.
2
[Role of inhaled corticosteroids in the management of COPD].
Pneumonol Alergol Pol. 2009;77(2):186-91.
3
Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
Pharmacotherapy. 2009 Aug;29(8):891-905. doi: 10.1592/phco.29.8.891.
4
[Pneumology. Inhaled corticosteroids in COPD: more and interesting data!].
Rev Med Suisse. 2008 Jan 16;4(140):155-7.
5
Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease.
Ann Pharmacother. 2010 Apr;44(4):613-22. doi: 10.1345/aph.1M243. Epub 2010 Mar 16.
6
Achieving therapeutic benefits of inhaled corticosteroids/beta2 agonist in chronic obstructive airway disease.
Chin Med J (Engl). 2007 Jun 20;120(12):1097-105.
7
Inhaled corticosteroids in severe COPD.
Lancet Respir Med. 2013 May;1(3):177-8. doi: 10.1016/S2213-2600(13)70042-0. Epub 2013 Apr 15.
8
Triple therapy for chronic obstructive pulmonary disease: trials catching up with clinical practice?
Am J Respir Crit Care Med. 2009 Oct 15;180(8):689-90. doi: 10.1164/rccm.200908-1205ED.
9
Economic evaluation of treating chronic obstructive pulmonary disease with inhaled corticosteroids and long-acting beta2-agonists in a health maintenance organization.
Respir Med. 2005 Dec;99(12):1534-45. doi: 10.1016/j.rmed.2005.03.018.
10
[Clinical effectiveness of synergic therapy].
Pol Merkur Lekarski. 2004 May;16 Suppl 1:20-2.
Zotero 插件